Global Hematological Cancers Market Survey Report With CAGR Forecast (2017-2021)

Hematological Cancers Market

Hematological Cancers Market

Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow, and include numerous forms of leukemia, lymphoma and myeloma. Hematological malignancies constituted 9% of all newly diagnosed malignancies in the US in 2011, with data indicating that lymphomas are more prevalent than leukemia or myeloma. Excluding acute lymphocytic leukemia and Hodgkin’s lymphoma, these types of malignancy are generally associated with increasing age. Therefore, considering the aging population globally, this class of malignancy is likely to become more prevalent.

Browse Complete Report With TOC @ http://www.marketresearchstore.com/report/frontier-pharma-hematological-cancers-highly-innovative-pipeline-66492

The report assesses first-in-class innovation in the hematological cancer pipeline, highlighting key trends in first-in-class product distribution. Analysis reveals that the hematological cancer pipeline is among the most innovative in the industry, with 463 first-in-class products, representing 45.3% of the pipeline with a disclosed molecular target.

The first-in-class targets in the pipeline are numerous and varied in nature. Cancer immunotherapies are the most common, with a total of 128 across all stages of development, followed by the signal transduction group of targets. The most commercially successful targeted drugs in the market fall into these two categories, including Rituxan (a cancer immunotherapy) and Gleevec (a signal transducer). The other target families have much fewer first-in-class products, reflecting the strong interest in cancer immunotherapies and targets implicated in signal transduction.

Over the past 15 years, the treatment of hematological malignancies has changed significantly, with the development of targeted therapies. These developments have been based on the growing understanding of the signaling pathways involved in disease pathogenesis. A notable example is the approval of Rituxan in 1997, which is used to treat multiple types of hematological malignancies, including Non-Hodgkin’s lymphoma. Analysis indicates that the current pipeline is following this trend of focusing on innovative, targeted therapies.

To Get Sample Copy of Report visit @ http://www.marketresearchstore.com/report/frontier-pharma-hematological-cancers-highly-innovative-pipeline-66492#RequestSample

Scope

The hematological cancers market is characterized by commercially successful therapies. 

  • Which classes of drug dominate the market?
  • What additional benefits have newly approved therapies brought to the market?

The pipeline contains a range of molecule types and molecular targets, with a strong emphasis on targeted therapies, as opposed to chemotherapeutic agents.

  • Which molecular targets appear most frequently in the pipeline?
  • To what degree is the pipeline penetrated by first-in-class innovation?
  • Which target families have the most first-in-class products?

First-in-class products differ substantially in their clinical potential, based on their alignment to disease-causing pathways.

  • How well are first-in-class targets aligned to known disease-causing pathways?
  • Which targets are specifically found in early-stage development?
  • Which are the most promising first-in-class targets in early-stage development?

There have been 284 licensing deals and 238 co-development deals pertaining to hematological cancer products since 2006.

  • Which territories show the most deal activity?
  • What were the trends in deal completion by product stage of development?
  • Which of the first-in-class products in development are not currently involved in a licensing or co-development deal, and therefore represent investment opportunities?

Leave a Reply

Your email address will not be published. Required fields are marked *